Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 8 of 8)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
6-Jan-10Global Markets DirectGlobal Markets DirectAltus Pharmaceuticals Inc. Financial and Strategic Analysis Review20$300  View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Comprehensive Rating Report48$99  View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Industry Report for DRUGS18$49  View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for ALTU13$25  View Abstract
29-Mar-09PriceTarget Research, Inc.N/AHealth Care Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards.65$40  View Abstract
28-Mar-09Pechala's ReportsFrantisek PechalaALTUS PHARMACEUTICALS INC (ALTU=US) 12-months forecast1$15  View Abstract
28-Mar-09Pechala's ReportsLubomir PechalaALTUS PHARMACEUTICALS INC (ALTU=US) 2-weeks forecast1$10  View Abstract
28-Mar-09Standard & Poor's Quantitative ReportN/AAltus Pharmaceuticals5$25  View Abstract
Independent Reports (Showing 1 to 8 of 8)
Release
Date [down]		 Contributor Author Title Pages Price More Info
6-Jan-10Global Markets DirectGlobal Markets DirectAltus Pharmaceuticals Inc. Financial and Strategic Analysis Review20$300View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Comprehensive Rating Report48$99View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Industry Report for DRUGS18$49View Abstract
30-Mar-09ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for ALTU13$25View Abstract
29-Mar-09PriceTarget Research, Inc.N/AHealth Care Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards.65$40View Abstract
28-Mar-09Pechala's ReportsFrantisek PechalaALTUS PHARMACEUTICALS INC (ALTU=US) 12-months forecast1$15View Abstract
28-Mar-09Pechala's ReportsLubomir PechalaALTUS PHARMACEUTICALS INC (ALTU=US) 2-weeks forecast1$10View Abstract
28-Mar-09Standard & Poor's Quantitative ReportN/AAltus Pharmaceuticals5$25View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.